New hope for kidney cancer: Real-World study tests vorolanib as Second-Line therapy
NCT ID NCT06676527
First seen Dec 16, 2025 · Last updated Jun 13, 2026 · Updated 31 times
Summary
This study looks at how well the drug vorolanib works for people with advanced kidney cancer that cannot be removed by surgery or has spread. It is for patients who need a second treatment after their first one stopped working. The study will track how long the cancer stays under control and any side effects, using real-world data from about 39 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinling Hospital
RECRUITINGNanjing, Jiangsu, 401520, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.